A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

Exclusion Criteria

• •1. Serum ALT ≥ 5 × ULN
• •2. Any clinically significant chronic or acute medical or psychiatric condition that makes the participant unsuitable for participation.
• •3. History of significant liver disease from non-HBV or non-HDV etiology
• •4. History of allergic reactions, hypersensitivity, or intolerance to study drug, its metabolites, or excipients.
• •5. History of anaphylaxis
• •6. History of immune complex disease
• •7. History of autoimmune disorder
• •8. Current therapy or therapy within 24 weeks of screening with an immunomodulatory agent, immune checkpoint inhibitors, immunosuppressants, cytotoxic or chemotherapeutic agent, or chronic systemic corticosteroids.
• •9. Any previous treatment with Bulivertide